Adam Lenkowsky: Celebrating the FDA approval of our new subcutaneous immunotherapy for patients with certain cancers
Adam Lenkowsky, Executive Vice President, Chief Commercialization Officer at Bristol Myers Squibb, reshared a post on LinkedIn by Bristol Myers Squibb adding:
“Today, we celebrate the FDA approval of our new subcutaneous immunotherapy for patients with certain cancers.
Ten years ago, we introduced our immunotherapy treatment option to patients, and since then, we’ve continued to follow the science.
This has led us to providing transformational treatment options to help elevate the standards of care.
Today’s approval builds on our legacy and is a testament to our commitment to delivering life-changing medicines to patients.
I am sincerely grateful to everyone whose collective efforts made this important milestone possible.”
Quoting Bristol Myers Squibb’s post:
“Our new FDA-approved immunotherapy treatment option for use by subcutaneous injection builds on our legacy of delivering transformational medicines.”
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023